Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight MaintenanceGlobeNewsWire · 2 days ago
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTSGlobeNewsWire · 4 days ago
GUTS CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Fractyl (NASDAQ: GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026Business Wire · 4 days ago
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law FirmPRNewsWire · 5 days ago
GUTS DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Fractyl (GUTS) Investors of Securities Class Action Lawsuit Deadline on October 20, 2026Newsfile Corp · 5 days ago
Deadline Alert: Fractyl Health, Inc. Investors Have Until October 20, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP RemindsGlobeNewsWire · 5 days agoFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$1.62 | -$1.92 | Miss |
| May 13, 2026 | -$0.17 | -$0.13 | Beat |
| Mar 24, 2026 | -$2.28 | -$2.04 | Beat |
| Nov 12, 2025 | -$4.08 | -$0.71 | Beat |
| Aug 13, 2025 | -$4.44 | -$4.20 | Beat |
| May 12, 2025 | -$5.40 | -$0.48 | Beat |